"The audit of company's formulation manufacturing facility at Duwada, Visakhapatnam, by the US FDA, has been completed on March 8, 2017. The company have been issued a Form 483 with 13 observations, which the company is addressing," Dr Reddy's Laboratories said in a BSE filing.
The company, however, did not specify the observations.
Shares of Dr Reddy's Laboratories were trading 4.21 per cent lower at Rs 2,731.35 on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content